The following bids, mergers, acquisitions and disposals were reported by 2030 GMT on Thursday:** U.S. specialty drugmaker Akorn Inc is exploring a bid for Belgian drugmaker UCB SA's U.S. subsidiary, a deal that would allow the company to move its tax domicile overseas, according to people familiar with the matter. UCB is looking to sell its U.S. specialty generics subsidiary, Kremers Urban Pharmaceuticals Inc, in a deal that could fetch as much as $2 billion.
Akorn, Inc. (Akom) is a manufacturer and markets a full line of diagnostic and therapeutic ophthalmic pharmaceuticals, as well as niche hospital drugs and injectable pharmaceuticals. Shares of AKRX traded higher by 3.36% or $1.23/share to $37.85. In the past year, the shares have traded as low as $18.11 and as high as $39.48. On average, 1181770 shares of AKRX exchange hands on a given day and today's volume is recorded at 2445668.
Source
